Multiple Aspirin Dose Analyses Reassured FDA On Brilinta’s U.S. Efficacy

The consistency of numerous analyses supporting a negative interaction between ticagrelor and high-dose aspirin, as used in the U.S., helped overcome FDA’s initial reluctance to approve AstraZeneca’s platelet inhibitor without a new trial.